Premium
P3‐358: CD200 negatively regulates β‐amyloid‐induced microglial activation and neuroinflammation in vivo and in vitro
Author(s) -
Lyons Anthony,
Lynch Marina A.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1900
Subject(s) - neuroinflammation , microglia , cd68 , cd40 , in vivo , tumor necrosis factor alpha , microbiology and biotechnology , inflammation , biology , chemistry , in vitro , immunology , immunohistochemistry , cytotoxic t cell , biochemistry
Cerebrolysin as reported. This beneficial effect continued on after the termination of Cerebrolysin treatment as evidenced by improved water maze where behavioral performance was still improved after 3 month of suspension of the Cerebrolysin therapy (age 6 months) in comparison to vehicle-treated controls. However after 6 months of suspension of Cerebrolysin the behavioral deficits reversed (age 9 months). The amelioration of the behavioral deficits at in the 0 and 3 months after suspension of CBL therapy correlated with improved synaptic complexity, while after 6 month of suspending the CBL therapy synaptic pathology was detected. Conclusions: The results indicate that the beneficial effects of Cerebrolysin persist for some time after the cessation of Cerebrolysin treatment.